Profile
Mary Martin is currently the Executive Chairman at Avectas Ltd.
She previously worked as the Managing Director-Biotechnology Drug Delivery Unit at Elan Corp.
Plc from 1989 to 2003.
From 2004 to 2012, she was the Chief Operating Officer & Executive Director at AGI Therapeutics Plc.
In 2014 to 2015, she worked as the SVP-Global Regulatory, Research & Development at Horizon Therapeutics Plc.
She also held the position of VP-Regulatory Affairs & Quality Assurance at HZNP USA LLC.
Mary Martin active positions
Companies | Position | Start |
---|---|---|
Avectas Ltd.
Avectas Ltd. Miscellaneous Commercial ServicesCommercial Services Avectas Ltd. provides cellular biotechnology solutions. It develops cell engineering technology called Solupore which permeabilizes the target cell membrane and allows transfer of cargo into cells. The company was founded by Shirley O? Dea and Michael Maguire in 2012 and is headquartered in Kildare, Ireland. | Chairman | 2016-06-30 |
Former positions of Mary Martin
Companies | Position | End |
---|---|---|
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 2015-12-17 |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | Chief Operating Officer | 2011-12-31 |
Elan Corp. Plc
Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Corporate Officer/Principal | 2002-12-31 |
HZNP USA LLC
HZNP USA LLC Pharmaceuticals: MajorHealth Technology HZNP USA LLC acquires, develops, markets and distributes specialty pharmaceutical products. The firm offers Actimmune, which is a bioengineered form of interferon gamma-1b, a protein that acts as a biologic response modifier through stimulation of the human immune system. Its Actimmune product is used for reducing the frequency and severity of serious infections related to chronic granulomatous diseases, and for delaying time to disease progression in patients with severe malignant osteopetrosis. The company was founded in 2011 by Balaji K. Venkataraman and Virinder Nohria and is headquartered in Lake Forest, FL. | General Counsel | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 5 |
---|---|
Elan Corp. Plc
Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | Health Technology |
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
HZNP USA LLC
HZNP USA LLC Pharmaceuticals: MajorHealth Technology HZNP USA LLC acquires, develops, markets and distributes specialty pharmaceutical products. The firm offers Actimmune, which is a bioengineered form of interferon gamma-1b, a protein that acts as a biologic response modifier through stimulation of the human immune system. Its Actimmune product is used for reducing the frequency and severity of serious infections related to chronic granulomatous diseases, and for delaying time to disease progression in patients with severe malignant osteopetrosis. The company was founded in 2011 by Balaji K. Venkataraman and Virinder Nohria and is headquartered in Lake Forest, FL. | Health Technology |
Avectas Ltd.
Avectas Ltd. Miscellaneous Commercial ServicesCommercial Services Avectas Ltd. provides cellular biotechnology solutions. It develops cell engineering technology called Solupore which permeabilizes the target cell membrane and allows transfer of cargo into cells. The company was founded by Shirley O? Dea and Michael Maguire in 2012 and is headquartered in Kildare, Ireland. | Commercial Services |
- Stock Market
- Insiders
- Mary Martin